title: Aspirin resistance: truth or dare.
abstract: Acetylsalicylic acid, or aspirin (ASA), is widely used in patients with cardiovascular disease to prevent acute ischemic events. However, platelet response to ASA is not equal in all individuals, and a high variability in the prevalence of ASA resistance is reported in the literature (0.4-83%). Actually, ASA resistance is poorly understood; this stems from the fact that its definition is unclear, its presence can be evaluated by a number of assays that are not equivalent, and its prevalence may vary widely based on the population studied. This article (1) exposes the difficulties in defining ASA resistance; (2) discusses the mechanisms by which ASA resistance may occur; (3) presents the characteristics that may put patients at greater risk of exhibiting ASA resistance; and (4) discusses the clinical impact of ASA resistance in patients requiring chronic therapy.
authors.affiliation: Faculty of Pharmacy, Université de Montréal, Montréal, Canada.
authors.forename: Marie
authors.initials: M
authors.lastname: Lordkipanidzé
authors.forename: Chantal
authors.initials: C
authors.lastname: Pharand
authors.forename: Donald A
authors.initials: DA
authors.lastname: Palisaitis
authors.forename: Jean G
authors.initials: JG
authors.lastname: Diodati
mesh_terms: D000818:Animals; D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use; D004351:Drug Resistance; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin